Bifalgorithm post · Research cancer 2025 · Monitoring Treatment Response and Predicting Resistance

Immune Response

Immune Response (Research cancer 2025 · Monitoring Treatment Response and Predicting Resistance) — "Early changes in ctDNA levels after starting treatment have…

Ideas in this flowchart

Clinical use of ctDNA for treatment monitoring and outcome prediction
Early changes in ctDNA levels can predict treatment outcome
ctDNA changes can also monitor the immune response
A phase II clinical trial evaluated early changes in tumor-agnostic ctDNA features
The changes were measured within the first week of starting pembrolizumab treatment
These ctDNA changes predicted progression-free survival and overall survival across solid tumors
ctDNA is positioned as a critical tool for predicting resistance and assessing treatment effectiveness
Ongoing research is exploring ctDNA use in pediatric cancers

Bifalgorithm

Feed/

Immune Response

No cover

Channel

Research cancer 2025

1 page

USR292600b83e2a

Ebook2w

"Early changes in ctDNA levels after starting treatment have also been used to predict treatment outcome and monitor immune response. In a phase II clinical trial, early changes in tumor-agnostic ctDNA features within the first week of starting treatment with the ICI pembrolizumab predicted both progression-free survival and overall survival across solid tumors (1084)Stutheit-Zhao EY, et al. (2024) Cancer Discov, 14: 1048..\n\nTogether, these findings position ctDNA as a critical tool for predicting resistance and assessing treatment effectiveness, with ongoing research also exploring its use in pediatric cancers (1085)Janssen FW, et al. (2024) NPJ Precis Oncol, 8: 172.."

Flowchart preview

👍

0 comments0 shares